GIMEMA multicenter pilot study: platelet count of evaluable patients after the end of the first therapy course
| . | Total . | At least 18 years of age through 70 years of age . | At least 2 years of age through 17 years of age . | P . | ||
|---|---|---|---|---|---|---|
| Total . | Less than 10 . | 10 or greater . | ||||
| Evaluable patients, n | 90 | 48 | 42 | 32 | 10 | NA |
| Median platelet count at fourth day of the first therapy cycle, × 109/L (range) | 92 (2-370) | 87 (2-290) | 99 (7-370) | 98 (7-271) | 110 (28-370) | NS |
| Platelets > 20 × 109/L, no. patients (%) | 68/75* (91) | 35/38* (92) | 33/37* (89) | 25/29* (86) | 8/8* (100) | NS |
| Platelets > 30 × 109/L, no. patients (%) | 76/90 (84) | 42/48 (87) | 34/42 (81) | 26/32 (81) | 8/10 (80) | NS |
| Platelets ≥ 50 × 109/L, no. patients (%) | 66/90 (73) | 38/48 (79) | 28/42 (67) | 21/32 (66) | 7/10 (70) | NS |
| . | Total . | At least 18 years of age through 70 years of age . | At least 2 years of age through 17 years of age . | P . | ||
|---|---|---|---|---|---|---|
| Total . | Less than 10 . | 10 or greater . | ||||
| Evaluable patients, n | 90 | 48 | 42 | 32 | 10 | NA |
| Median platelet count at fourth day of the first therapy cycle, × 109/L (range) | 92 (2-370) | 87 (2-290) | 99 (7-370) | 98 (7-271) | 110 (28-370) | NS |
| Platelets > 20 × 109/L, no. patients (%) | 68/75* (91) | 35/38* (92) | 33/37* (89) | 25/29* (86) | 8/8* (100) | NS |
| Platelets > 30 × 109/L, no. patients (%) | 76/90 (84) | 42/48 (87) | 34/42 (81) | 26/32 (81) | 8/10 (80) | NS |
| Platelets ≥ 50 × 109/L, no. patients (%) | 66/90 (73) | 38/48 (79) | 28/42 (67) | 21/32 (66) | 7/10 (70) | NS |
NA indicates not applicable; NS, not significant.
Patients with platelet count ≤ 20 × 109/L at enrollment.